0.7749
Precedente Chiudi:
$0.7741
Aprire:
$0.8
Volume 24 ore:
1.60M
Relative Volume:
2.19
Capitalizzazione di mercato:
$45.50M
Reddito:
-
Utile/perdita netta:
$-123.46M
Rapporto P/E:
-0.2992
EPS:
-2.59
Flusso di cassa netto:
$-104.11M
1 W Prestazione:
+44.44%
1M Prestazione:
+109.38%
6M Prestazione:
+131.24%
1 anno Prestazione:
-55.21%
Bioatla Inc Stock (BCAB) Company Profile
Nome
Bioatla Inc
Settore
Industria
Telefono
858-558-0708
Indirizzo
11085 TORREYANA ROAD, SAN DIEGO
Confronta BCAB con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BCAB
Bioatla Inc
|
0.7749 | 39.23M | 0 | -123.46M | -104.11M | -2.59 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-08-13 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
2024-11-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
2022-09-15 | Iniziato | JMP Securities | Mkt Outperform |
2022-05-05 | Downgrade | Credit Suisse | Outperform → Neutral |
2022-03-21 | Iniziato | H.C. Wainwright | Buy |
2021-10-15 | Ripresa | BTIG Research | Buy |
2021-06-28 | Iniziato | ROTH Capital | Buy |
2021-05-05 | Ripresa | Credit Suisse | Outperform |
2021-04-26 | Ripresa | Credit Suisse | Outperform |
2021-01-11 | Iniziato | BTIG Research | Buy |
2021-01-11 | Iniziato | Credit Suisse | Outperform |
2021-01-11 | Iniziato | JP Morgan | Overweight |
2021-01-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Bioatla Inc Borsa (BCAB) Ultime notizie
BioAtla Inc. stock trend forecast2025 AllTime Highs & Stepwise Trade Signal Implementation - newser.com
BioAtla Inc. stock chart pattern explained2025 Market Overview & Long-Term Growth Portfolio Plans - newser.com
Can trapped investors hope for a rebound in BioAtla Inc.Earnings Trend Report & Low Risk Entry Point Tips - Newser
Key metrics from BioAtla Inc.’s quarterly dataTrade Signal Summary & Daily Chart Pattern Signal Reports - Newser
Will BioAtla Inc. benefit from macro trends2025 Growth vs Value & Real-Time Volume Triggers - Newser
Is BioAtla Inc. stock ready for a breakout2025 Major Catalysts & Weekly Sector Rotation Insights - Newser
Can BioAtla Inc. recover in the next quarter2025 Key Lessons & AI Forecasted Entry and Exit Points - Newser
Short interest data insights for BioAtla Inc.Earnings Risk Report & Weekly Watchlist for Consistent Profits - Newser
Earnings visualization tools for BioAtla Inc.2025 Earnings Surprises & Technical Buy Zone Confirmations - Newser
BioAtla Inc.’s volatility index tracking explainedQuarterly Market Review & Technical Confirmation Alerts - Newser
Using Bollinger Bands to evaluate BioAtla IncMarket Performance Summary & Consistent Profit Focused Trading Strategies - Newser
Published on: 2025-09-12 13:57:40 - Newser
What machine learning models say about BioAtla Inc.Weekly Profit Summary & Fast Moving Stock Watchlists - Newser
Is BioAtla Inc. stock reversal real or fake2025 Price Targets & Weekly High Return Opportunities - Newser
Risk adjusted return profile for BioAtla Inc. analyzedInsider Buying & Technical Entry and Exit Tips - Newser
Applying chart zones and confluence areas to BioAtla Inc.2025 Price Targets & Daily Market Momentum Tracking - Newser
When is the best time to exit BioAtla Inc.2025 Market WrapUp & Growth Focused Stock Reports - Newser
How to monitor BioAtla Inc. with trend dashboardsBuy Signal & Momentum Based Trading Signals - Newser
Tick level data insight on BioAtla Inc. volatilityEarnings Overview Summary & Short-Term Swing Trade Alerts - Newser
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma Following Productive Type B Meeting with FDA - Investing News Network
BioAtla stock holds Market Perform rating at JMP as FDA aligns on Phase 3 design By Investing.com - Investing.com South Africa
BioAtla stock holds Market Perform rating at JMP as FDA aligns on Phase 3 design - Investing.com Canada
Will BioAtla Inc. rebound enough to break evenEarnings Overview Report & High Return Stock Watch Alerts - Newser
BioAtla announces outcomes from Type B FDA meeting on ozuriftamab vedotin - TipRanks
Tools to monitor BioAtla Inc. recovery probabilityMarket Movers & Fast Gain Swing Trade Alerts - Newser
What institutional flow reveals about BioAtla Inc.Trend Reversal & Capital Protection Trade Alerts - Newser
FDA aligns with BioAtla on phase 3 trial design for cancer drug By Investing.com - Investing.com South Africa
Is BioAtla Inc. forming a breakout patternJobs Report & Long-Term Safe Investment Ideas - beatles.ru
Bioatla Inc Azioni (BCAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):